NCT05580562Phase 3Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Study sponsor: Jazz Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06Estimated
Enrollment · participants510Estimated
Source updated2026-04-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Overall survival (OS) Measure: Progression free survival (PFS) as assessed by using RANO-HGG criteria. After: Measure: Overall survival (OS).

Planned enrollment increased by 60 participants

Before: 450 participants (planned). After: 510 participants (planned).

Primary completion date changed

Before: Aug 2026. After: Jun 2028.

Check registry source